JACC:罕见基因突变与心源性猝死相关

2019-11-21 不详 MedSci原创

来自49个基因的罕见突变可以增加导致心源性猝死的4个重要危险因素的发生率:心肌病、冠心病、遗传性心律失常和主动脉病或主动脉夹层。本研究的目的旨在评估心源性猝死病例中罕见致病性变异的患病率,以及这种变异在无症状成人人群中的患病率和临床重要性。本研究纳入分析了600例成年起病的心源性猝死患者和600正常对照,并对其进行了全外显子测序分析,最终识别出了5178个基因突变,其中14个被认为是致病突变或可能

来自49个基因的罕见突变可以增加导致心源性猝死的4个重要危险因素的发生率:心肌病、冠心病、遗传性心律失常和主动脉病或主动脉夹层。本研究的目的旨在评估心源性猝死病例中罕见致病性变异的患病率,以及这种变异在无症状成人人群中的患病率和临床重要性。

本研究纳入分析了600例成年起病的心源性猝死患者和600正常对照,并对其进行了全外显子测序分析,最终识别出了5178个基因突变,其中14个被认为是致病突变或可能致病突变,这14个突变出现在15名心源性猝死患者中,致病基因突变在患者中的发生率为2.5%,对照中为0(p < 0.0001)。另外,又在4525名无症状的成年人中进行了验证,有41名(0.9%)携带致病或可能致病突变,经过平均14.3年时间的随访,这些携带者的心血管死亡风险比其他人高3.24倍(p = 0.02)。

本研究在成年心源性猝死患者中筛选出了致病或可能致病的基因突变,这些突变在无症状的成年人中发生率近1%。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854576, encodeId=ea3618545e6cd, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 06 02:44:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945983, encodeId=aedb1945983a1, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Aug 12 03:44:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326402, encodeId=576c1326402db, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467500, encodeId=7a0c146e500c9, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593510, encodeId=f305159351082, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2020-02-06 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854576, encodeId=ea3618545e6cd, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 06 02:44:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945983, encodeId=aedb1945983a1, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Aug 12 03:44:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326402, encodeId=576c1326402db, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467500, encodeId=7a0c146e500c9, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593510, encodeId=f305159351082, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854576, encodeId=ea3618545e6cd, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 06 02:44:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945983, encodeId=aedb1945983a1, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Aug 12 03:44:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326402, encodeId=576c1326402db, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467500, encodeId=7a0c146e500c9, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593510, encodeId=f305159351082, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854576, encodeId=ea3618545e6cd, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 06 02:44:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945983, encodeId=aedb1945983a1, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Aug 12 03:44:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326402, encodeId=576c1326402db, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467500, encodeId=7a0c146e500c9, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593510, encodeId=f305159351082, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 syscxl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854576, encodeId=ea3618545e6cd, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Feb 06 02:44:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945983, encodeId=aedb1945983a1, content=<a href='/topic/show?id=93e3e9546d6' target=_blank style='color:#2F92EE;'>#罕见基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79546, encryptionId=93e3e9546d6, topicName=罕见基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed Aug 12 03:44:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326402, encodeId=576c1326402db, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467500, encodeId=7a0c146e500c9, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593510, encodeId=f305159351082, content=<a href='/topic/show?id=9850510e9a3' target=_blank style='color:#2F92EE;'>#心源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51079, encryptionId=9850510e9a3, topicName=心源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=955718147815, createdName=mhm295, createdTime=Sat Nov 23 00:44:00 CST 2019, time=2019-11-23, status=1, ipAttribution=)]
    2019-11-23 mhm295

相关资讯

JACC:ST段抬高型心梗患者应该选哪种冠脉支架?

目前,对于接受经皮冠脉介入治疗(PCI)的ST段抬高型心梗(STEMI)患者,尚无特异有效的药物洗脱支架(DES)被证实优于其他支架。本次荟萃分析研究的目的旨在比较和评估不同冠脉支架在STEMI患者中的安全性和有效性。 本研究回顾分析了来自15个随访时间超过12个月临床研究的10979名PCI患者(男性占77.3%,平均年龄为60.7岁),主要终点事件是心源性死亡、再梗死和靶血管血运重建的复

JACC:外科瓣膜术后永久起搏器植入的危险因素研究

需要永久起搏器(PPM)的心脏瓣膜手术后传导障碍的危险因素尚不清楚。本研究的目的旨在探究二尖瓣或主动脉瓣外科术后PPM植入的时间和危险因素。本研究纳入分析了77882名接受了二尖瓣或主动脉瓣外科手术的患者,主要终点事件是术后1年内的PPM植入。其中,有63.8%的患者接受了主动脉瓣置换术(AVR),18.9%患者接受了二尖瓣置换术(MVR),10.5%的患者接受了二尖瓣修复术(MVr),5.4%患

Heart:严重三尖瓣反流伴充血性心衰患者的预后分析

部分严重三尖瓣反流(TR)和充血性心衰(CHF)是接受药物治疗,而非手术治疗。本研究目的旨在比较和评估接受三尖瓣手术(TVS)和没有接受手术患者的临床特征和预后。本研究回顾分析了数据库中2556名严重TR患者,并排除接受心脏移植和没有充血性心衰的患者。最终,共纳入分析了534名严重TR和CHF患者,仅55名患者接受了TVS治疗。在479名没有接受手术治疗的患者中,有30%有手术指征。经过38个月的

Nutri Metab Cardiovas:降低心衰风险、延长心血管疾病患者寿命,间歇性禁食益处多多!

导语:间歇性禁食最初因“网红减肥法”而被大家所熟知,近些年更因为其可改善类风湿性关节炎、多发性硬化症以及糖尿病患者的病情而备受热议。

JACC:他汀类药物的使用与认知力下降不呈相关性

他汀类药物可能与记忆和认知力下降相关,本研究的目的旨在评估老年患者他汀类药物使用和记忆与认知力变化的相关性。本研究纳入分析了MAS研究中的1037名70-90岁的患者,经过6年时间的随访,发现相比于从未使用他汀类药物的患者,他汀类药物使用者的记忆和认知力无明显差异,观察期间他汀类药物的启动与减缓记忆衰退的速度有关。探索性分析发现,使用他汀类药物与心脏病和载脂蛋白Eε4携带者的特异性记忆测试表现减弱

Eur Heart J:Alirocumab对急性冠脉综合征患者心血管预后的影响

由此可见,在新近的ACS患者中,Alirocumab可改善患者结局,且与年龄无关。这表明降低LDL-C是ACS老年患者重要的预防干预措施。